Early time to relapse as a survival prognosticator in nodal mature T-cell lymphomas: results from the PETAL consortium
Year: 2025
Type: article
Study design: Observational Study
Abstract: ABSTRACT: We assessed the overall survival (OS) impact of time to relapse (TTR) in multinational cohorts with independent observational and randomized validation. Patients with nMTCL with frontline complete response were assigned to TTR12 (≤12 months) or without TTR12 based on time to progression or next therapy. OS analyses included modified landmark (m-LM), standard landmark (s-LM), and time-dependent Cox (td-Cox), adjusting for age, histology, and prognostic index for T-cell lymphoma (PIT) score. Across 452 patients, 165 (36.5%) had TTR12, 181 (40%) relapsed at ≥12 months, and 106 (23.5%) remained relapse-free. TTR12 conferred worse OS using m-LM (hazard ratio [HR], 2.14; 95% confidence interval [CI], 1.58-2.90; P< .001), s-LM (HR, 1.92; 95% CI, 1.39-2.66; P< .001); and td-Cox (HR, 5.81; 95% CI, 2.94-11.46; P< .001). Results were consistent in the independent validation cohorts. TTR12 consistently conferred worse OS irrespective of frontline stem cell transplantation or PIT score, in peripheral T-cell lymphoma, not otherwise specified (m-LM: HR, 2.32; 95% CI, 1.51-3.55; P< .001; s-LM: HR, 2.10; 95% CI, 1.33-3.31; P = .001), anaplastic large cell lymphoma (m-LM: HR, 3.34; 95% CI, 1.18-9.50; P = .023; s-LM: HR, 2.96; 95% CI, 1.02-8.81; P = .046), and angioimmunoblastic T-cell/T follicular helper cell lymphoma (m-LM only: HR, 1.92; 95% CI, 1.15-3.21; P = .013). Second-line novel therapies improved OS (second-line start to death) vs chemotherapy in TTR12 only (HR, 0.60; 95% CI, 0.37-0.97; P = .038; without TTR12: HR, 0.82; 95% CI, 0.51-1.32; P = .407). TTR12 serves as a prognostic and potential OS surrogate marker, supporting stratification of new risk groups and need for their differential treatment.
Source: Blood
Authors: Mark N. Sorial, Luis E. Malpica Castillo, Carlos Chiattone, Edith Julia, Emmanuel Bachy, Stefan K. Barta, Robert Stuver, Eric Jacobsen, Massimo Federico, Hasmukh Jain, H. Miles Prince, Francine Foss, Pier Luigi Zinzani, Takeshi Okatani, Won-Seog Kim, Estelle Verburgh, Mubarak Al-Mansour, Maria Elena Cabrera, Govind Bhagat, Changyu Shen, Salvia Jain
Institutions: Massachusetts General Hospital, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, Hospices Civils de Lyon, Hôpital Lyon Sud, Lyon 1 Université, Hospital of the University of Pennsylvania, University of Pennsylvania, Memorial Sloan Kettering Cancer Center, Harvard University, University of Modena and Reggio Emilia, Homi Bhabha National Institute, Tata Memorial Hospital, The University of Melbourne, Peter MacCallum Cancer Centre, Yale Cancer Center, Yale University, Istituto di Ematologia di Bologna, University of Bologna, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Samsung Medical Center, Sungkyunkwan University, University of Cape Town, Groote Schuur Hospital, King Abdulaziz Medical City, Hospital del Salvador, University of Chile, Columbia University Irving Medical Center, Columbia University, Biogen (United States), Massachusetts Institute of Technology, Broad Institute
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,500
Funders: Eli Lilly and Company, AstraZeneca, Sanofi, Massachusetts General Hospital, Gilead Sciences, Biogen, Celgene, University of Virginia, Astex Pharmaceuticals, Mersana Therapeutics, BeiGene, Incyte, Celltrion, Seagen, Kyowa Hakko Kirin, Servier, Intas Pharmaceuticals, National Institutes of Health, Irving Medical Center, Columbia University, Pharmacyclics, National Cancer Institute, Daiichi Sankyo Europe, Cilag
OpenAlex ID: W4417042368